January 2025
Denali Therapeutics Faces Another Setback in ALS Treatment Development
Denali Therapeutics, ALS, Phase II/III trial, HEALEY ALS Platform trial, DNL343, treatment failure
Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol
Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial
FDA Sets Efficacy Threshold for Obesity Therapies Amid Market Expansion
FDA, obesity therapies, weight-loss treatments, efficacy standards, obesity market trends
Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda
2024 FDA Approvals: Breakthroughs in Cancer and Rare Diseases
FDA approvals, 2024, cancer treatments, rare diseases, novel drugs
Tune Therapeutics Secures $175M to Advance Epigenetic Editing into Clinical Trials
Epigenetic editing, gene therapy, Tune Therapeutics, clinical trials, biotech funding
Insilico Medicine and Menarini Group’s Stemline Therapeutics Announce Second Exclusive Licensing Agreement for AI-Discovered Oncology Drug Candidate
Insilico Medicine, Menarini Group, Stemline Therapeutics, AI-generated cancer drug, Oncology drug candidate, Licensing agreement, $550 million deal
Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies
Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform
Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment
Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy
Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes
Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials